Novartis Venture Fund

The Novartis Venture Fund was created to foster innovation, drive significant patient benefit, and generate superior returns by nurturing and investing in innovative life science companies. Our fund invests in a wide array of companies working in biotechnology and biopharmaceuticals at various stages of growth and development. We manage over USD 750 million in committed capital and more than 40 portfolio companies across North America and Europe. Through the Novartis Venture Fund, we look to grow and develop novel therapeutics and platforms that we believe will address unmet patient needs across the healthcare spectrum and the world. Whether an early-stage startup or later-stage company, we take a hands-on approach to investment, working closely with the board and management to deliver real clinical impact.